INTERNATIONAL AIDS VACCINE INITIATIVE INC

Their core work

IAVI is a US-based nonprofit product development organization dedicated to translating scientific discoveries into vaccines and antibodies against HIV, tuberculosis, and emerging infectious diseases. They run their own research laboratories and clinical trial networks, and coordinate large international consortia that take candidate vaccines from immunogen design through Phase I/II human trials. Their contribution to European consortia is deep expertise in HIV prophylactic and therapeutic vaccine development, immunology and virology platforms, and the regulatory and trial-design know-how needed to move candidates into humans.

What they specialise in

How they've shifted over time

The two projects sit almost back-to-back (2015 and 2016), so this is less an evolution and more a continuous, deepening commitment to European HIV vaccine R&D. The shift visible in the data is from a broader EAVI2020 participation into the much larger, more platform-oriented EHVA alliance, where IAVI's role expanded to cover immunology, virology, trial design, and data integration. The trajectory shows them consolidating as a transatlantic anchor partner for Europe's HIV vaccine pipeline.

They are consolidating as Europe's go-to non-EU partner for HIV prophylactic and therapeutic vaccine programmes, a natural fit for any future Horizon Europe consortium on infectious-disease vaccines.

How they like to work

IAVI joins as a participant — never coordinator — in very large European consortia (61 partners across 19 countries from only two projects). They act as a specialist scientific partner bringing US-based vaccine R&D capacity into EU-led alliances, rather than running the projects themselves. Working with them means tapping a product-development organization with its own labs and global trial network, but expecting EU coordination to stay on the European side.

A highly connected network of 61 partners spanning 19 countries, built almost entirely through two large HIV vaccine alliances. The geographic footprint is strongly European with a transatlantic bridge back to the US.

What sets them apart

IAVI is one of the few non-EU organizations sitting inside Europe's major HIV vaccine consortia, bringing a rare combination of nonprofit mission, in-house vaccine development labs, and decades of experience running early-phase trials in both high- and low-income settings. Most European health research partners are universities or hospitals; IAVI is a product development partnership, which means they think in terms of getting a candidate to market, not just publications. For a consortium building an infectious-disease vaccine pipeline, they offer a translational bridge that few academic partners can match.

Highlights from their portfolio

• EHVA
  By far their largest H2020 engagement (EUR 4.39M) — the European HIV Vaccine Alliance is the flagship EU platform for discovering and evaluating novel prophylactic and therapeutic HIV vaccines.
• EAVI2020
  Their entry point into H2020 HIV vaccine work — the European AIDS Vaccine Initiative 2020 built the consortium foundation that EHVA later expanded.